Goldman's Haider: Pivotal Year for Obesity Market in Pharma

Bloomberg Published Updated Economy
Sign in to save

Why it matters

Goldman Sachs predicts 2026 to be a pivotal year for the obesity market due to upcoming oral drug launches, with investor psychology closely tied to their performance.

Expected market reaction

Bullish Confidence 80% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 80% confidence.

Evidence trail

Evidence
Source Bloomberg
Claim Goldman's Haider: Pivotal Year for Obesity Market in Pharma
AI inference Bullish · 80%
Generated 2026-02-02 23:39

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
40620

Original source

Asad Haider, head of the U.S. Healthcare Business Unit at Goldman Sachs Research, says 2026 is a pivotal year for the obesity market due to upcoming oral drug launches. He tells Romaine Bostick and Katie Greifeld on “The Close” that investor psychology around the sector this year will be closely tied to how those launches perform. (Source: Bloomberg)

Read the full article on Bloomberg

Original article published by Bloomberg on February 3, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage

This model on similar stories

Llama 3.1 8B Instant (Groq) · 40.5% correct across 1187 scored calls on indices See the full record